English | Nanologica

Interim Report Q2 2023 Nanologica AB (publ)

7 July, 2023

FINANCIAL SUMMARY– Net sales for the second quarter amounted to TSEK 672 (210) and for the half-year to TSEK 1,026 (479)– The operating loss for the quarter amounted to TSEK -13,312 (-12,397) and for the half-year to TSEK -24,032 (-27,989)– Loss after tax for the quarter amounted to TSEK -14,671 (-13,473) and for the half-year to TSEK -26,764 (-29,388)– Earnings per share before and after dilution were SEK -0.41 (-0.48) for the quarter and SEK

Nanologica Delivers Silica to Latin-American Customer for Production of Insulin

1 June, 2023

As a result of Nanologica's product in preparative chromatography, NLAB Saga®, reaching internal quality requirements, silica is now delivered to a customer in Latin America for production of diabetes drugs. The customer is a latin-american pharmaceutical manufacturer that manufactures, among other things, insulin and insulin analogues. This delivery refers to silica for the production of insulin. The delivery is made against a recent order with an order value of about TSEK 300. ”We have for some

Nanologica Presents at Redeye Growth Day

25 May, 2023

On June 1, CEO Andreas Bhagwani will present the latest developments in Nanologica at Redeye Growth Day. The "In Focus" interview will be broadcast live andcan be followed via https://www.redeye.se/events/871323/redeye-growth-day. An introduction to the company before the event can be seen here https://www.redeye.se/video/company-prerecorded-presentation/910855/nanologica. For further information, please contactJohanna JohanssonDirector IR, Communications and Marketingjohanna.johansson@nanologica.com+46 72 211 21 90 About Nanologica AB (publ)Nanologica manufactures and sells nanoporous silica particles for applications within life science. A proprietary production method

Changes in Nanologica’s Group Structure and Management Team for Full Focus on Chromatography

8 May, 2023

Nanologica AB (publ) has decided to focus on Chromatography and the management team is adapted to reflect the new business focus. In order to create the best conditions for success in preparative chromatography, the company's operations are focused on Chromatography and the Drug Development operations are down-prioritized and placed in subsidiaries for future opportunities. The management team is adapted to reflect this and CSO Gary Pitcairn and VP Drug Development Ulf Ericsson will leave the

Bulletin from the AGM Nanologica AB (publ)

4 May, 2023

Stockholm, May 4, 2023 – Nanologica AB (publ) today held its Annual General Meeting, at which the following resolutions were adopted. Adoption of the income statement and balance sheet, disposition of profit or lossThe Annual General Meeting adopted the income statement and balance sheet for the company and for the group in accordance with the presented accounting documents and resolved, in accordance with the board's proposal, that the accumulated loss of SEK -47,447,399 be carried

Nanologica’s Product within Preparative Chromatography Reaches Quality Requirements

3 May, 2023

After successfully implementing fine-tuning in production, Nanologica's product now meets the company's own requirements for quality in all evaluated parameters. The company is therefore continuing to formally approve products to be able delivery to customers progressively. ”After making further fine-tunings in one of the production steps, we now have a product that we are satisfied with and that we can proudly deliver to customers. Finally! This means that we now can move on with the first

About us

Nanologica is a Swedish nanotechnology company, world-leading in the development of nanoporous silica particles for purification by chromatography. A proprietary production method enables the company to create supreme products by precisely controlling the shape, size, porosity, and surface properties of silica particles. Nanologica provides products of high-quality silica used in the purification of peptide drugs. These products can contribute to lower costs and higher production for pharmaceutical manufacturers, which increases the availability of cost-effective medicines and gives more people around the world access to vital treatment for diabetes and obesity. Nanologica is headquartered in Södertälje and Nanologica’s share (NICA) is listed on Nasdaq Stockholm Main Market.